Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.

Front Oncol · 2020 · PMC7735156 · PMID 33330050

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

close to being significantno p-value reported

Although the difference of the combination treatment compared with CEA-TCB monotherapy was only close to being significant, data support a trend for improved efficacy of the combination effect.

also in 274 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.